Protalix Biotherapeutics, Inc. (PLX)
2.37
+0.07
(+3.04%)
USD |
NYAM |
Jul 07, 16:00
2.36
-0.01
(-0.42%)
After-Hours: 20:00
Protalix Biotherapeutics EPS Diluted (Quarterly) : 0.2206 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.2206 |
| December 31, 2025 | -0.0684 |
| September 30, 2025 | 0.0291 |
| June 30, 2025 | 0.002 |
| March 31, 2025 | -0.0472 |
| December 31, 2024 | 0.0856 |
| September 30, 2024 | 0.0336 |
| June 30, 2024 | -0.03 |
| March 31, 2024 | -0.0629 |
| December 31, 2023 | -0.0828 |
| September 30, 2023 | -0.0432 |
| June 30, 2023 | 0.2114 |
| March 31, 2023 | -0.0545 |
| December 31, 2022 | -0.0728 |
| September 30, 2022 | -0.0721 |
| June 30, 2022 | -0.1127 |
| March 31, 2022 | -0.0499 |
| December 31, 2021 | -0.1464 |
| September 30, 2021 | -0.0922 |
| June 30, 2021 | -0.2474 |
| March 31, 2021 | -0.1371 |
| December 31, 2020 | 0.0114 |
| September 30, 2020 | -0.135 |
| June 30, 2020 | -0.1279 |
| March 31, 2020 | 0.0959 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.0196 |
| September 30, 2019 | -0.2399 |
| June 30, 2019 | -0.5218 |
| March 31, 2019 | -0.4895 |
| December 31, 2018 | -0.3662 |
| September 30, 2018 | -0.3591 |
| June 30, 2018 | -0.577 |
| March 31, 2018 | -0.6469 |
| December 31, 2017 | -1.10 |
| September 30, 2017 | -0.90 |
| June 30, 2017 | -0.60 |
| March 31, 2017 | -4.80 |
| December 31, 2016 | -0.2114 |
| September 30, 2016 | -0.70 |
| June 30, 2016 | -1.10 |
| March 31, 2016 | -0.90 |
| September 30, 2015 | -0.40 |
| June 30, 2015 | -0.50 |
| March 31, 2015 | -0.60 |
| December 31, 2014 | -0.90 |
| September 30, 2014 | -0.90 |
| June 30, 2014 | -0.70 |
| March 31, 2014 | -0.80 |
| December 31, 2013 | -1.20 |
| September 30, 2013 | -0.60 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Altimmune, Inc. | -0.1813 |
| Humacyte, Inc. | -0.089 |
| Agenus, Inc. | 1.023 |
| Amgen, Inc. | 3.344 |
| Anika Therapeutics, Inc. | -0.3737 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 18.32M |
| Revenue (Quarterly) | 33.75M |
| Total Expenses (Quarterly) | 15.43M |
| Enterprise Value | 142.00M |
| Gross Profit Margin (Quarterly) | 87.77% |
| Profit Margin (Quarterly) | 54.27% |
| Earnings Yield | 7.73% |
| Operating Earnings Yield | 10.26% |
| Normalized Earnings Yield | 7.734 |